Every Form 4 that Crescent Biopharma, Inc. (CBIO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CBIO filings page.
CRESCENT BIOPHARMA, INC. (CBIO) reported that officer Ryan Lynch, its Treasurer, Senior Vice President of Finance and Chief Accounting Officer, sold 240 Ordinary Shares on September 16, 2026 at a weighted average price of $17.90 per share in an open-market or private transaction. According to the company’s disclosure, these shares were automatically sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted on December 15, 2025 and were carried out under a Rule 10b5-1 instruction adopted on February 25, 2026 solely to cover taxes related to that vesting. Following this sale, Lynch directly holds 13,631 Ordinary Shares.
CRESCENT BIOPHARMA, INC. (CBIO) reported that Chief Scientific Officer Jan Pinkas sold 658 Ordinary Shares on September 16, 2026 at a weighted average price of $17.90 per share. The shares were automatically sold to satisfy tax withholding obligations upon settlement of previously granted restricted stock units, under a Rule 10b5-1 trading instruction. Following this sale, Pinkas directly holds 21,581 Ordinary Shares.
CRESCENT BIOPHARMA, INC. (CBIO) reported that its Chief Medical Officer, Ellie Eunkyung Im, sold 623 Ordinary Shares on September 16, 2026 at a weighted average price of $17.90 per share, leaving her with 21,446 shares held directly.
According to the company’s disclosure, these shares were automatically sold to satisfy tax withholding obligations arising from the settlement of restricted stock units granted on December 15, 2025, and were effected pursuant to a Rule 10b5-1 trading instruction adopted on February 25, 2026. The price reflects multiple trades between $17.10 and $19.17 per share.
CRESCENT BIOPHARMA, INC. (CBIO) reported that Chief Financial Officer Richard William Scalzo sold 568 Ordinary Shares on September 16, 2026 in an open-market transaction at a weighted average price of $17.90 per share. The shares were automatically sold to satisfy tax withholding obligations from vesting restricted stock units under a Rule 10b5-1 trading instruction. Following this sale, he directly holds 19,730 Ordinary Shares.
CRESCENT BIOPHARMA, INC. (CBIO) reported that its General Counsel and Corporate Secretary, Barbara Harlin Bispham, sold 620 Ordinary Shares on September 16, 2026, primarily to satisfy tax withholding obligations on vesting restricted stock units. The weighted average sale price was $17.90 per share, with prices ranging from $17.10 to $19.17. After this tax-related sale, she directly holds 18,710 Ordinary Shares. The transaction was executed under a Rule 10b5-1 trading instruction adopted on February 25, 2026.
CRESCENT BIOPHARMA, INC. (CBIO) reported that Chief Executive Officer and director Joshua T. Brumm sold Ordinary Shares in two transactions, totaling 9,447 shares, on September 16 and September 18, 2026. According to the company’s disclosure, the shares were automatically sold to satisfy tax withholding obligations upon settlement of previously granted restricted stock units and were effected under a Rule 10b5-1 trading instruction adopted on February 28, 2026.
CRESCENT BIOPHARMA, INC. (CBIO) reported that President and COO Jonathan McNeill sold a total of 4,570 Ordinary Shares in open market transactions on September 16 and 18, 2026. The sales were made under a Rule 10b5-1 trading instruction adopted on February 25, 2026 and were executed solely to cover tax withholding obligations tied to vesting restricted stock units.
Fairmount Healthcare Fund II L.P., an entity associated with Crescent Biopharma, indirectly purchased 853,450 Ordinary Shares at $14.50 and Pre-Funded Warrants for 525,897 shares at $14.499 on July 16, 2026. The Pre-Funded Warrants are exercisable at $0.001 per share, have no expiration, and are subject to a 9.99% beneficial ownership cap.
After these purchases, Fairmount Healthcare Fund II L.P. indirectly held 3,601,316 Ordinary Shares and Pre-Funded Warrants for 2,294,037 shares. Fairmount Funds Management LLC, Peter Harwin, and Tomas Kiselak disclaim beneficial ownership beyond their pecuniary interest.
CRESCENT BIOPHARMA, INC. officer Ryan Lynch reported an open-market sale of 465 Ordinary Shares on June 22, 2026 at a weighted average price of $17.99 per share. These shares were automatically sold to satisfy tax withholding obligations tied to the settlement of restricted stock units granted on December 15, 2025, under a pre-arranged Rule 10b5-1 instruction adopted on February 25, 2026. Following this tax-related sale, Lynch directly holds 13,871 Ordinary Shares.
CRESCENT BIOPHARMA, INC. Chief Scientific Officer Jan Pinkas reported an open-market sale of 1,288 Ordinary Shares at a weighted average price of $17.99 per share. According to the disclosure, these shares were automatically sold to cover tax withholding obligations arising from the settlement of previously granted restricted stock units.
The sale was executed under a pre-arranged Rule 10b5-1 instruction adopted on February 26, 2026, indicating it was planned in advance specifically to pay taxes on vesting rather than a discretionary portfolio decision. Following the transaction, Pinkas directly holds 22,239 Ordinary Shares.
CRESCENT BIOPHARMA, INC. Chief Financial Officer Richard William Scalzo reported an open-market sale of 1,112 ordinary shares at a weighted average price of $17.99 per share. According to the disclosure, these shares were automatically sold to satisfy tax withholding obligations tied to vested restricted stock units granted on December 15, 2025.
The sales were executed under a pre-arranged Rule 10b5-1 instruction adopted on February 25, 2026, solely to cover taxes from the RSU vesting. After this transaction, Scalzo directly holds 20,298 ordinary shares, indicating he retains a substantial equity position in the company.
CRESCENT BIOPHARMA, INC. officer Barbara Harlin Bispham reported an automatic sale of 1,218 Ordinary Shares on June 22, 2026 to cover taxes from restricted stock units vesting. The weighted average sale price was $17.99 per share, with individual trades ranging from $16.88 to $18.86. These transactions were executed under a pre-arranged Rule 10b5-1 instruction solely to satisfy tax withholding obligations. After the sale, she directly holds 19,330 Ordinary Shares.
CRESCENT BIOPHARMA, INC. Chief Medical Officer Ellie Eunkyung Im reported an open-market sale of 1,219 Ordinary Shares at a weighted average price of $17.99 per share. The footnotes explain these shares were automatically sold to satisfy tax withholding obligations tied to the vesting of restricted stock units.
The sales were executed under a pre-arranged Rule 10b5-1 instruction adopted on February 25, 2026, and were intended solely to cover taxes from the RSU settlement. After this transaction, the reporting person directly holds 22,069 Ordinary Shares.
CRESCENT BIOPHARMA, INC. President and COO Jonathan McNeill reported an open-market sale of 20,549 Ordinary Shares at a weighted average price of $17.99 per share. According to the filing, the shares were automatically sold to cover tax withholding obligations from vesting restricted stock units under a pre-arranged Rule 10b5-1 instruction. After these tax-related sales, McNeill directly holds 139,158 Ordinary Shares.
CRESCENT BIOPHARMA, INC. director and Chief Executive Officer Joshua T. Brumm reported an automatic sale of ordinary shares primarily related to equity compensation taxes. On June 22, 2026, he sold 42,305 ordinary shares at a weighted average price of $17.99 per share.
According to the disclosure, these shares were automatically sold to satisfy tax withholding obligations from the settlement of restricted stock units granted on December 15, 2025 and March 17, 2025, under a Rule 10b5-1 instruction adopted on February 28, 2026. Following the transaction, Brumm directly holds 281,212 ordinary shares of Crescent Biopharma.
CRESCENT BIOPHARMA, INC. director Jonathan Violin received a grant of stock options covering 11,050 ordinary shares. The options carry an exercise price of $17.01 per share and expire on June 2, 2036. They vest in full on the earlier of June 2, 2027 or the company’s next annual shareholder meeting, subject to his continued service.
CRESCENT BIOPHARMA, INC. director David Charles Lubner received a grant of stock options covering 11,050 ordinary shares. The options have an exercise price of $17.01 per share and expire on June 2, 2036. They vest in full on the earlier of June 2, 2027 or the company’s next annual shareholder meeting, subject to his continued service.
CRESCENT BIOPHARMA, INC. director Alexandra Balcom received a grant of stock options covering 11,050 ordinary shares. The options have an exercise price of $17.01 per share and expire on June 2, 2036.
The grant vests in full on the earlier of June 2, 2027 or the date of the company’s next annual meeting of shareholders, as long as she continues serving the company. Following this grant, she holds options on 11,050 shares directly, reflecting routine equity-based compensation rather than an open-market purchase or sale.
CRESCENT BIOPHARMA, INC. director Susan Moran received a grant of options to buy 11,050 ordinary shares. The options have an exercise price of $17.01 per share and expire on June 2, 2036. They vest in full on the earlier of June 2, 2027 or the company’s next annual shareholder meeting, subject to her continued service, leaving her with 11,050 derivative securities directly held after this transaction.
CRESCENT BIOPHARMA, INC. reported an insider equity award involving investment entities affiliated with Fairmount Funds. A stock option for 11,050 ordinary shares was granted at an exercise price of $17.0100 per share, expiring on June 2, 2036.
The option was awarded to Peter Harwin, who holds it for one or more investment vehicles managed by Fairmount Funds Management LLC. It vests in full on the earlier of June 2, 2027 or the company’s next annual shareholder meeting, subject to his continued service. Fairmount, Harwin, and Tomas Kiselak state they disclaim beneficial ownership beyond any pecuniary interest.
Crescent Biopharma’s Chief Scientific Officer reports new equity grants. On December 15, 2025, the officer acquired 17,507 and 5,000 Ordinary Shares, for a total of 22,507 Ordinary Shares beneficially owned directly after the transactions.
The filing also discloses a stock option grant for 70,025 Ordinary Shares at an exercise price of $13.21 per share, expiring on December 15, 2035. These options vest in 1/48th monthly installments from December 15, 2025, while the related Restricted Stock Units vest in approximately equal three‑month installments over four years, in each case contingent on continued service.
Crescent Biopharma, Inc. reported new equity awards to its Chief Business Officer, Christopher Doughty. On December 15, 2025, he acquired 14,714 and 8,000 ordinary shares through awards of restricted stock units (RSUs). Each RSU represents a right to receive one ordinary share, vesting in roughly equal three‑month installments over four years from December 15, 2025, as long as he continues to work for the company or its subsidiaries.
On the same date, Doughty also received a stock option covering 58,855 ordinary shares at an exercise price of $13.21 per share, expiring on December 15, 2035. This option vests in monthly installments, with 1/48th of the option vesting on each monthly anniversary of December 15, 2025, subject to continued service. After these transactions, he beneficially owned 62,194 ordinary shares and 58,855 options, all held directly.
Crescent Biopharma, Inc. reported new equity awards to its Chief Executive Officer and director, Joshua T. Brumm, as of December 15, 2025. He acquired 45,117 Ordinary Shares and an additional 10,000 Ordinary Shares, bringing his total beneficial ownership to 323,517 Ordinary Shares held directly.
Brumm also received a stock option giving him the right to buy 180,467 Ordinary Shares at an exercise price of $13.21 per share, expiring on December 15, 2035. The option vests in equal monthly installments of 1/48th each month starting from December 15, 2025, while the related Restricted Stock Units vest in approximately equal three‑month installments over four years from that same date, in each case conditioned on his continued service to Crescent Biopharma or its subsidiaries.
Crescent Biopharma, Inc. reported an equity compensation grant to its Chief Financial Officer, who is an officer and reporting person of the company. On December 15, 2025, the officer received 14,422 Ordinary Shares in the form of Restricted Stock Units (RSUs), each representing the right to receive one Ordinary Share as they vest. The RSUs are scheduled to vest in approximately equal three‑month installments over four years from December 15, 2025, conditioned on continued service.
On the same date, the officer was also granted a stock option to purchase 57,688 Ordinary Shares at an exercise price of $13.21 per share, expiring on December 15, 2035. This option vests as to 1/48th of the option on each monthly anniversary of December 15, 2025, also subject to continued employment or service with Crescent Biopharma or its subsidiaries.
Crescent Biopharma, Inc. reported an insider equity grant for its President and COO, Jonathan McNeill. On December 15, 2025, he acquired 19,507 and 6,000 Ordinary Shares as awards of restricted stock units (RSUs), and now directly beneficially owns 159,707 Ordinary Shares.
The RSUs each represent a right to receive one Ordinary Share and will vest in approximately equal three-month installments over four years from December 15, 2025, contingent on continued service. He also received a stock option for 78,029 Ordinary Shares at an exercise price of $13.21 per share, expiring on December 15, 2035. This option vests as to 1/48th of the grant on each monthly anniversary of December 15, 2025, subject to continued employment or service.
Crescent Biopharma, Inc. reported new equity awards to its Chief Medical Officer, Ellie Im. On December 15, 2025, she acquired a total of 21,298 Ordinary Shares in the form of Restricted Stock Units (RSUs), shown as two grants of 16,298 and 5,000 shares. Each RSU represents a contingent right to receive one Ordinary Share, vesting in approximately equal three-month installments over four years from December 15, 2025, as long as she continues to work for the company or its subsidiaries.
She also received a stock option covering 65,190 Ordinary Shares at an exercise price of $13.21 per share. This option vests as to 1/48th of the grant on each monthly anniversary of December 15, 2025, subject to continued service, and is exercisable until December 15, 2035.
Crescent Biopharma, Inc. reported new equity awards to officer Ryan Lynch, who serves as Treasurer, Senior Vice President of Finance and Chief Accounting Officer. On December 15, 2025, Lynch acquired 8,378 Ordinary Shares and an additional 4,000 Ordinary Shares through awards of Restricted Stock Units (RSUs), bringing his directly held Ordinary Shares to 12,378.
Each RSU represents a contingent right to receive one Ordinary Share, vesting in approximately equal three‑month installments through the four‑year anniversary of December 15, 2025, contingent on continued service. Lynch also received a stock option for 33,512 Ordinary Shares at an exercise price of $13.21 per share, exercisable until December 15, 2035. This option vests as to 1/48th of the grant on each monthly anniversary of December 15, 2025, also conditioned on continuous employment or service.
Crescent Biopharma, Inc. reported an equity compensation grant to an executive officer. On December 15, 2025, the reporting person received 12,422 Ordinary Shares and an additional 6,000 Ordinary Shares as Restricted Stock Units, bringing their beneficial ownership to 18,422 Ordinary Shares. The RSUs vest in approximately equal three‑month installments over four years from December 15, 2025, contingent on continued service.
The officer was also granted a stock option for 72,185 Ordinary Shares at an exercise price of $13.21 per share, exercisable until December 15, 2035. This option vests as to 1/48th of the grant on each monthly anniversary of December 15, 2025, as long as the officer remains employed by or provides services to Crescent Biopharma or its subsidiaries.